https://www.diabesityrounds.com/a/twiist-automated-insulin-delivery-in-type-2-diabetes-13-week-single-arm-trialDiabesity Roundsen2026-10-10T05:34:34.881Ztwiist automated insulin delivery in type 2 diabetes: 13-week single-arm trialhttps://www.diabesityrounds.com/a/semaglutide-in-diabetic-kidney-disease-primary-mri-outcomes-not-met-in-52-week-tDiabesity Roundsen2026-10-10T05:33:48.517ZSemaglutide in diabetic kidney disease: primary MRI outcomes not met in 52-week trialhttps://www.diabesityrounds.com/a/ada-and-easd-2026-consensus-earlier-sglt2-inhibitor-or-glp-1-use-in-type-2-diabeDiabesity Roundsen2026-10-10T05:32:23.876ZADA and EASD 2026 consensus: earlier SGLT2 inhibitor and/or GLP-1-based therapy in type 2 diabeteshttps://www.diabesityrounds.com/a/resmetirom-effects-in-mash-were-similar-across-common-risk-genotypesDiabesity Roundsen2026-10-10T05:25:58.423ZResmetirom effects in MASH were similar across common risk genotypeshttps://www.diabesityrounds.com/a/oral-safiglipron-versus-dapagliflozin-in-type-2-diabetes-phase-3-trial-in-chinaDiabesity Roundsen2026-10-10T05:25:14.003ZOral safiglipron versus dapagliflozin in type 2 diabetes: phase 3 trial in Chinahttps://www.diabesityrounds.com/a/chemically-synthesised-semaglutide-hd1916-matches-wegovy-for-weight-loss-in-chinDiabesity Roundsen2026-10-10T05:24:23.810ZChemically synthesised semaglutide HD1916 met equivalence with Wegovy for weight loss in Chinese adultshttps://www.diabesityrounds.com/a/nearly-one-in-four-indigenous-adults-in-odisha-had-impaired-kidney-function-in-aDiabesity Roundsen2026-10-10T05:24:06.706ZNearly one in four indigenous adults in Odisha had impaired kidney function in a surveyhttps://www.diabesityrounds.com/a/triple-agonist-ubt251-lowered-body-weight-over-24-weeks-in-a-phase-2-trialDiabesity Roundsen2026-10-10T05:23:29.186ZTriple agonist UBT251 lowered body weight over 24 weeks in a phase 2 trial